CEVA Stock Analysis: CEVA | NASDAQ
Semiconductors | NASDAQ, USA | Market Cap: 688m USD | 12M Return: -3.6% | US1572101053 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.5M
Qual. Beats: -1
Rev. Trend: 94.4%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
CEVA, Inc. (NASDAQ: CEVA) is a U.S.-based semiconductor intellectual property (IP) company headquartered in Rockville, Maryland, founded in 1999 and formerly known as ParthusCeva, Inc. The company licenses silicon IP and software to semiconductor firms and OEMs across the U.S., Europe, the Middle East, and Asia Pacific. Its product portfolio spans connectivity IP for 5G/5G-Advanced baseband (PentaG-RAN, XC20/XC21/XC23 DSPs), Bluetooth, Wi-Fi, ultra-wideband, and NB-IoT cellular modems (Ceva-Waves family), as well as audio/sensor processing (SensPro, ClearVox, RealSpace, MotionEngine) and neural processing units for embedded and generative AI (Ceva-NeuPro-M and NeuPro-Nano).
CEVA operates in the semiconductor IP sub-industry, licensing reusable chip designs and DSP architectures to chipmakers rather than manufacturing its own silicon. This fabless, royalty-and-license-based model is common among IP vendors such as ARM and Synopsys, allowing the company to monetize designs across a wide range of end markets including mobile, IoT, automotive, and wireless infrastructure.
- 5G-Advanced baseband IP royalties expand with infrastructure buildout
- NeuPro NPU adoption accelerates AI licensing revenue
- Smartphone royalty revenue exposed to consumer demand cycles
| Net Income: -10.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 3.57 > 1.0 |
| NWC/Revenue: 219.5% < 20% (prev 176.4%; Δ 43.10% < -1%) |
| CFO/TA 0.03 > 3% & CFO 11.2m > Net Income -10.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.3m) vs 12m ago 18.30% < -2% |
| Gross Margin: 86.71% > 18% (prev 87.17%; Δ -0.46% > 0.5%) |
| Asset Turnover: 33.42% > 50% (prev 35.14%; Δ -1.72% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.65 (Total Current Assets 281.4m - Total Current Liabilities 25.9m) / Total Assets 390.6m |
| B: -0.02 (Retained Earnings -9.69m / Total Assets 390.6m) |
| C: -0.02 (EBIT TTM -6.68m / Avg Total Assets 348.3m) |
| D: 7.10 (Book Value of Equity 342.4m / Total Liabilities 48.2m) |
| Altman-Z'' = 11.53 = AAA |
| DSRI: 0.33 (Receivables 17.8m/49.7m, Revenue 116.4m/107.5m) |
| GMI: 1.01 (GM 87.17% / 86.71%) |
| AQI: 0.80 (AQ_t 0.21 / AQ_t-1 0.27) |
| SGI: 1.08 (Revenue 116.4m / 107.5m) |
| TATA: -0.06 (NI -10.8m - CFO 11.2m) / TA 390.6m) |
| Beneish M = -3.64 (Cap -4..+1) = AAA |
As of November 13, 2026, the stock is trading at USD 26.32 with a total of 354,172 shares traded. Over the past week, the price has changed by +7.17%, over one month by -17.10%, over three months by -13.53% and over the past year by -3.55%.
Current recommended Stop Loss: 21.70 (which is 17.6% or 2 ATR below the current price).
CEVA has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy CEVA.
- StrongBuy: 7
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 38.2 | 45.2% |
P/E Forward = 35.461
P/S = 5.9132
P/B = 2.0443
P/EG = 1.7757
Revenue TTM = 116.4m USD
EBIT TTM = -6.68m USD
EBITDA TTM = -3.04m USD
Long Term Debt = 14.0m USD (estimated: total debt 16.8m - short term 2.80m)
Short Term Debt = 2.80m USD (from shortTermDebt, last quarter)
Debt = 16.8m USD (from shortLongTermDebtTotal, last quarter) (leases 16.8m already included)
Net Debt = -203.8m USD (calculated: Debt 16.8m - CCE 220.7m)
Enterprise Value = 484.5m USD (688.4m + Debt 16.8m - CCE 220.7m)
Interest Coverage Ratio = unknown (Ebit TTM -6.68m / Interest Expense TTM 0.0)
EV/FCF = 85.67x (Enterprise Value 484.5m / FCF TTM 5.66m)
FCF Yield = 1.17% (FCF TTM 5.66m / Enterprise Value 484.5m)
FCF Margin = 4.86% (FCF TTM 5.66m / Revenue TTM 116.4m)
Net Margin = -9.25% (Net Income TTM -10.8m / Revenue TTM 116.4m)
Gross Margin = 86.71% ((Revenue TTM 116.4m - Cost of Revenue TTM 15.5m) / Revenue TTM)
Gross Margin QoQ = 85.37% (prev 87.44%)
Tobins Q-Ratio = 1.24 (Enterprise Value 484.5m / Total Assets 390.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 16.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -5.28m (EBIT -6.68m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.88 (Total Current Assets 281.4m / Total Current Liabilities 25.9m)
Debt / Equity = 0.05 (Debt 16.8m / totalStockholderEquity, last quarter 342.4m)
Debt / EBITDA = 67.03 (negative EBITDA) (Net Debt -203.8m / EBITDA -3.04m)
Debt / FCF = -36.04 (Net Debt -203.8m / FCF TTM 5.66m)
Total Stockholder Equity = 339.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.09% (Net Income -10.8m / Total Assets 390.6m)
RoE = -3.17% (Net Income TTM -10.8m / Total Stockholder Equity 339.3m)
RoCE = -1.89% (EBIT -6.68m / Capital Employed (Equity 339.3m + L.T.Debt 14.0m))
RoIC = -1.46% (negative operating profit) (NOPAT -5.28m / Invested Capital 361.7m)
WACC = 15.74% (E(688.4m)/V(705.2m) * Re(16.12%) + D(16.8m)/V(705.2m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 16.12% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 89.51 | Cagr: 8.39%
[DCF] Terminal Value 54.01% ; FCFF base≈5.66m ; Y1≈5.68m ; Y5≈6.02m
[DCF] Fair Price = 8.72 (EV 41.5m - Net Debt -203.8m = Equity 245.4m / Shares 28.2m; r=15.74% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -3.04 | # QB: -1
Revenue Correlation: 94.41 | Revenue CAGR: 7.49% | SUE: -3.11 | # QB: -1
EPS current Quarter (2027-03-31): EPS=0.10 | Chg30d=-13.55% | Revisions=-50% | Analysts=8
EPS current Year (2026-12-31): EPS=0.53 | Chg30d=-3.96% | Revisions=+70% | GrowthEPS=+25.3% | GrowthRev=+10.5%
EPS next Year (2027-12-31): EPS=0.76 | Chg30d=-5.67% | Revisions=+25% | GrowthEPS=+43.8% | GrowthRev=+14.5%
[Analyst] Revisions Ratio: +17% (up=9, down=6)